AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1661630 — intervention group
Group type: COMPARATOR
Intervention: high content of roughage diet (20 g of fibers) and 10 g of bran
Number of subjects: 114
Study 6806486 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended field megavoltage irradiation
Number of subjects: 0
Study 6806486 — intervention group
Group type: COMPARATOR
Intervention: Delayed androgen ablation
Number of subjects: 0
Study 4076325 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (up to 120 mg t.i.d.)
Number of subjects: 11
Study 4076325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29264689 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning (AM) administration of gonadotropins (uFSH and hMG)
Number of subjects: 127
Study 29264689 — intervention group
Group type: COMPARATOR
Intervention: Evening (PM) administration of gonadotropins (uFSH and hMG)
Number of subjects: 127
Study 26863355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 451
Study 26863355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 24169019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural thrombotic events (IPTEs)
Number of subjects: 3163
Study 22446490 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 21
Study 22446490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg)
Number of subjects: 21
Study 22446490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20811348 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of AZD3480 (10- and 50-fold higher exposures than a 20-mg dose)
Number of subjects: 0
Study 20811348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20811348 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of AZD3480 and 20-mg dosing
Number of subjects: 0
Study 20811348 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic doses of AZD3480
Number of subjects: 0
Study 20811348 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3480
Number of subjects: 0
Study 18985291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning assessed by the Trail-Making Test B at the onset of long-term treatment
Number of subjects: 125
Study 18985291 — intervention group
Group type: COMPARATOR
Intervention: Initial clinical status
Number of subjects: 125
Study 18985291 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of neuropsychological and psychopathological variables
Number of subjects: 125
Study 16162695 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular albuterol nebulizations every 4 hours
Number of subjects: 62
Study 16162695 — intervention group
Group type: COMPARATOR
Intervention: Ad-lib albuterol nebulizations (saline solution nebulizations every 4 hours)
Number of subjects: 62
Study 12631003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 40
Study 12631003 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 40
Study 10694618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (0.5 microg. kg(‐1). min(‐1))
Number of subjects: 30
Study 8654326 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A (extensive quantitative food frequency questionnaire)
Number of subjects: 241
Study 8654326 — intervention group
Group type: EXPERIMENTAL
Intervention: Method B (novel shorter quantitative food frequency questionnaire with a 14 day food record)
Number of subjects: 241
Study 8654326 — intervention group
Group type: EXPERIMENTAL
Intervention: Method B
Number of subjects: 241
Study 1476278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingual) + 100 mg oral hydroxyzine
Number of subjects: 60
Study 1476278 — intervention group
Group type: COMPARATOR
Intervention: Control (100 mg oral hydroxyzine)
Number of subjects: 60
Study 6097521 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2 x 0.05 mg/day) and low-dose conjugated estrogens (0.6 mg/day)
Number of subjects: 83
Study 6097521 — intervention group
Group type: COMPARATOR
Intervention: Higher dosage estrogens (1.25 mg/day)
Number of subjects: 83
Study 31246237 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 652
Study 31246237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 652
Study 31246237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 652
Study 29306517 — intervention group
Group type: EXPERIMENTAL
Intervention: Study A participants (younger; preserved eGFR)
Number of subjects: 929
Study 29306517 — intervention group
Group type: EXPERIMENTAL
Intervention: Study B participants (older; reduced eGFR)
Number of subjects: 929
Study 29306517 — intervention group
Group type: EXPERIMENTAL
Intervention: Study A participants with prolonged stable eGFRs
Number of subjects: 929
Study 29306517 — intervention group
Group type: EXPERIMENTAL
Intervention: Study B participants with stable eGFRs
Number of subjects: 929
Study 29306517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprogressors in both studies
Number of subjects: 929
Study 27048170 — intervention group
Group type: EXPERIMENTAL
Intervention: BAN2401 (0.1 mg/kg to 10 mg/kg biweekly for four months)
Number of subjects: 0
Study 27048170 — intervention group
Group type: EXPERIMENTAL
Intervention: BAN2401
Number of subjects: 0
Study 25194077 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser ablation of prostate
Number of subjects: 36
Study 25194077 — intervention group
Group type: COMPARATOR
Intervention: pTURP
Number of subjects: 36
Study 22794216 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 17% EDTA for 10 minutes + 10 mL of 1% NaOCl for 1 minute
Number of subjects: 48
Study 22794216 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 5% EDTA for 10 minutes + 10 mL of 1% NaOCl for 1 minute
Number of subjects: 48
Study 22794216 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 17% EDTA for 1 minute + 10 mL of 1% NaOCl for 1 minute
Number of subjects: 48
Study 22794216 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 5% EDTA for 1 minute + 10 mL of 1% NaOCl for 1 minute
Number of subjects: 48
Study 22794216 — intervention group
Group type: COMPARATOR
Intervention: 10 mL distilled water for 10 minutes
Number of subjects: 48
Study 18760492 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin administration
Number of subjects: 0
Study 17699836 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa mixed with Hib
Number of subjects: 0
Study 17699836 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa and Hib coadministered
Number of subjects: 0
Study 17699836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed DTPa-based and Hib vaccines
Number of subjects: 0
Study 17699836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed DTPw-based and Hib vaccines
Number of subjects: 0
Study 17699836 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-based/Hib combination vaccines
Number of subjects: 0
Study 16270845 — intervention group
Group type: EXPERIMENTAL
Intervention: CWT with enhanced incentives (n = 11)
Number of subjects: 19
Study 16270845 — intervention group
Group type: COMPARATOR
Intervention: CWT (n = 8)
Number of subjects: 19
Study 12047324 — intervention group
Group type: COMPARATOR
Intervention: LAM group (30 mg of lansoprazole once daily, 500 mg of amoxicillin and 250 mg of metronidazole thrice daily for 2 weeks)
Number of subjects: 135
Study 12047324 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMP group (same as LAM group plus 18,000 tyrosine units of pronase thrice daily for 2 weeks)
Number of subjects: 135
Study 12047324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronase (used in LAMP group)
Number of subjects: 135
Study 9614676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold meal (4 degrees C)
Number of subjects: 10
Study 9614676 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature meal (37 degrees C)
Number of subjects: 10
Study 9614676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot meal (55 degrees C)
Number of subjects: 10
Study 9614676 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 37 degrees C and 55 degrees C meals
Number of subjects: 10
Study 7532501 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care home support team (immediate service)
Number of subjects: 0
Study 7532501 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (service after one month)
Number of subjects: 0
Study 2644331 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor diet high in sugar
Number of subjects: 0
Study 2644331 — intervention group
Group type: COMPARATOR
Intervention: Good diet without sugar
Number of subjects: 0
Study 773735 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide HCl
Number of subjects: 27
Study 30697914 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine physiotherapy with cupping therapy
Number of subjects: 56
Study 30697914 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 56
Study 28003221 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal strain in anterior myocardial wall
Number of subjects: 1064
Study 28003221 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal strain in lateral myocardial wall
Number of subjects: 1064
Study 28003221 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal strain in inferior myocardial wall
Number of subjects: 1064
Study 28003221 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal strain in septal myocardial wall
Number of subjects: 1064
Study 28003221 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior longitudinal strain as a predictor of VT/VF
Number of subjects: 1064
Study 28003221 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior longitudinal strain as a predictor of VT/VF
Number of subjects: 1064
Study 28003221 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial function in inferior wall including B-type natriuretic peptide
Number of subjects: 1064
Study 28003221 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain from inferior myocardial wall for predicting VT/VF
Number of subjects: 1064
Study 26448178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (200 mg twice daily)
Number of subjects: 96
Study 26448178 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg once daily for 4 weeks on treatment; 2 weeks off)
Number of subjects: 96
Study 26448178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 96
Study 26448178 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 96
Study 24271647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg) for 14 days
Number of subjects: 19
Study 24271647 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 19
Study 21169716 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training for 6 weeks
Number of subjects: 12
Study 21169716 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 12
Study 19751559 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive anti-Candida treatment based on corrected colonization index (CCI) when CCI >= 0.4 and evidence of sepsis; treatment not given when CCI < 0.4, but given if the patient's condition worsened.
Number of subjects: 110
Study 17225720 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.05% fluticasone propionate
Number of subjects: 60
Study 17225720 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.03% tacrolimus
Number of subjects: 60
Study 17225720 — intervention group
Group type: COMPARATOR
Intervention: Complementary fusidic acid
Number of subjects: 60
Study 17225720 — intervention group
Group type: COMPARATOR
Intervention: Fusidic acid treatment
Number of subjects: 60
Study 15554580 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2DG)
Number of subjects: 151
Study 15554580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 12003253 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low-dose transdermal nicotine
Number of subjects: 0
Study 9152688 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 50
Study 9152688 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 50
Study 7953879 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic application (800-1299 gauss)
Number of subjects: 23
Study 7953879 — intervention group
Group type: COMPARATOR
Intervention: Nonmagnetic application
Number of subjects: 23
Study 3828583 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable masker
Number of subjects: 21
Study 3828583 — intervention group
Group type: COMPARATOR
Intervention: Placebo apparatus
Number of subjects: 21
Study 29048234 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 180
Study 29048234 — intervention group
Group type: COMPARATOR
Intervention: Parent Education Program (PEP)
Number of subjects: 180
Study 29048234 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Education Program (PEP-R)
Number of subjects: 180
Study 29048234 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT-R)
Number of subjects: 180
Study 26859064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200mg once daily for six days
Number of subjects: 353
Study 26859064 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 600mg twice daily for 10 days
Number of subjects: 353
Study 24055595 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (dronabinol)
Number of subjects: 28
Study 24055595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22110122 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS-steered treatment in ACPA-positive patients
Number of subjects: 508
Study 22110122 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS-steered treatment in ACPA-negative patients
Number of subjects: 508
Study 22110122 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial monotherapy in ACPA-positive patients
Number of subjects: 508
Study 20969662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with intradermal cross-linked hyaluronic acid and onabotulinumtoxinA
Number of subjects: 22
Study 20969662 — intervention group
Group type: COMPARATOR
Intervention: Cross-linked hyaluronic acid monotherapy
Number of subjects: 22
Study 17624209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) plus PCA
Number of subjects: 80
Study 17624209 — intervention group
Group type: COMPARATOR
Intervention: PCA alone
Number of subjects: 80
Study 16360446 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitor (rofecoxib 25 mg/day)
Number of subjects: 96
Study 16360446 — intervention group
Group type: COMPARATOR
Intervention: No COX‐2 inhibitor
Number of subjects: 96
Study 12502178 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline ingestion (50 mg/kg body weight)
Number of subjects: 13
Study 12502178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8599618 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian access (group A)
Number of subjects: 87
Study 8599618 — intervention group
Group type: COMPARATOR
Intervention: Brachial access (group B)
Number of subjects: 87
Study 2501509 — intervention group
Group type: EXPERIMENTAL
Intervention: TEN (Vivonex TEN)
Number of subjects: 75
Study 2501509 — intervention group
Group type: COMPARATOR
Intervention: TPN (Freamine HBC 6.9% and Trophamine 6%)
Number of subjects: 75
Study 2501509 — intervention group
Group type: EXPERIMENTAL
Intervention: TEN
Number of subjects: 75
Study 2501509 — intervention group
Group type: COMPARATOR
Intervention: TPN
Number of subjects: 75
Study 336498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 40
Study 336498 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 40
Study 31329607 — intervention group
Group type: COMPARATOR
Intervention: Position 0 cm (foot in full contact with footplate)
Number of subjects: 14
Study 31329607 — intervention group
Group type: EXPERIMENTAL
Intervention: Position 8 cm (chair moved forward)
Number of subjects: 14
Study 31329607 — intervention group
Group type: EXPERIMENTAL
Intervention: Position 6 cm
Number of subjects: 14
Study 31329607 — intervention group
Group type: COMPARATOR
Intervention: Position 0 cm
Number of subjects: 14
Study 31329607 — intervention group
Group type: EXPERIMENTAL
Intervention: Position 8 cm
Number of subjects: 14
Study 29050163 — intervention group
Group type: EXPERIMENTAL
Intervention: Open decompression group
Number of subjects: 84
Study 29050163 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneously looped thread transection group
Number of subjects: 84
Study 29050163 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 84
Study 26833223 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Cogmed Working Memory Training® (CWMT)
Number of subjects: 120
Study 26833223 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive Cogmed Working Memory Training® (CWMT)
Number of subjects: 120
Study 26833223 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping for LMX1A‐rs4657412 TT(AA) genotype
Number of subjects: 120
Study 26833223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid analysis
Number of subjects: 120
Study 23658479 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT-R
Number of subjects: 470
Study 21823552 — intervention group
Group type: EXPERIMENTAL
Intervention: MoxDuo 12 mg/8 mg
Number of subjects: 197
Study 21823552 — intervention group
Group type: EXPERIMENTAL
Intervention: MoxDuo 6 mg/4 mg
Number of subjects: 197
Study 19210951 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (2.5 to 15 mg/day, mean dose 9.0 mg/day) for 12 weeks
Number of subjects: 24
Study 19210951 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment with aripiprazole
Number of subjects: 24
Study 16709537 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV vaccine
Number of subjects: 0
Study 16709537 — intervention group
Group type: COMPARATOR
Intervention: DTPa-HBV plus IPV
Number of subjects: 0
Study 14726726 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.25 mg/kg body weight
Number of subjects: 60
Study 14726726 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg body weight
Number of subjects: 60
Study 14726726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14726726 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (both doses)
Number of subjects: 60
Study 14726726 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior ratings (responders vs nonresponders)
Number of subjects: 60
Study 11739299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg/d, n=18)
Number of subjects: 35
Study 11739299 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (750 mg/d, n=17)
Number of subjects: 35
Study 10075214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position during the second stage of labor
Number of subjects: 248
Study 10075214 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position during the second stage of labor
Number of subjects: 248
Study 10075214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position during the second stage of labor (in group with history of episiotomy)
Number of subjects: 248
Study 10075214 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position during the second stage of labor (in group with history of episiotomy)
Number of subjects: 248
Study 7999655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Proparacaine (P)
Number of subjects: 42
Study 7999655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% Proparacaine (P)
Number of subjects: 42
Study 7999655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Proparacaine (P) after 10 minutes
Number of subjects: 42
Study 7999655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% Proparacaine (P) after 10 minutes
Number of subjects: 42
Study 7999655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Proparacaine (P) after first instillation
Number of subjects: 42
Study 7999655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% Proparacaine (P) after first instillation
Number of subjects: 42
Study 2656340 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (10 micrograms) of SMS 201-995
Number of subjects: 26
Study 2656340 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (50 micrograms) of SMS 201-995
Number of subjects: 26
Study 2656340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31288603 — intervention group
Group type: EXPERIMENTAL
Intervention: Young talkers (20s)
Number of subjects: 72
Study 31288603 — intervention group
Group type: EXPERIMENTAL
Intervention: Old talkers (50s to 60s)
Number of subjects: 72
Study 31288603 — intervention group
Group type: EXPERIMENTAL
Intervention: Listeners from Seoul (n=30) in follow-up experiment
Number of subjects: 72
Study 29374054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (n = 101)
Number of subjects: 610
Study 29374054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 90)
Number of subjects: 610
Study 29374054 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib vs Placebo among patients with PD-L1+ tumors
Number of subjects: 610
Study 27818309 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic support for loop diuretic adherence monitoring
Number of subjects: 40
Study 27818309 — intervention group
Group type: COMPARATOR
Intervention: Passive adherence monitoring alone
Number of subjects: 40
Study 26200158 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized dental anesthesia
Number of subjects: 20
Study 26200158 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental anesthesia
Number of subjects: 20
Study 23972529 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone 30 minutes before a memory encoding task
Number of subjects: 64
Study 23972529 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone 210 minutes before a memory encoding task
Number of subjects: 64
Study 23972529 — intervention group
Group type: COMPARATOR
Intervention: Placebo at both times
Number of subjects: 64
Study 21795500 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin and ibandronate plus screening
Number of subjects: 31